Top

Published in:

01-12-2008 | CLINICAL TRIAL UPDATES AND HOTLINE SESSIONS

Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008

Authors: Dr. med. Patrick Müller, MD, Stephan Rosenkranz, Oliver Adam, Florian Custodis, Michael Böhm

Published in: Clinical Research in Cardiology | Issue 12/2008

Abstract

This article summarizes the results of a number of clinical trials in the field of cardiovascular medicine which were presented during the Hotline and Clinical Trial Update Sessions at the annual meeting of the European Society of Cardiology, held in Munich, Germany, from 30th August to 3rd September 2008. The data were presented by leading experts in the field with relevant positions in the trials. It is important to note that unpublished reports should be considered as preliminary data, as the analysis may change in the final publications. The comprehensive summaries have been generated from the oral presentation and the webcasts of the European Society of Cardiology and should provide the readers with the most comprehensive information on diagnostic and therapeutic developments in cardiovascular medicine.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, HORIZONS-AMI Trial Investigators (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230PubMedCrossRef

Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D’Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A (2008) Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118:1172–1182PubMedCrossRef

Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:807–816PubMedCrossRef

Reil JC, Böhm M (2007) The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 96:585–592PubMedCrossRef

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372:817–821PubMedCrossRef

Reil JC, Böhm M (2008) BEAUTIFUL results-the slower, the better? Lancet 372:779–780PubMedCrossRef

Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M (2006) Management of elderly patients with congestive heart failure—design of the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Am Heart J 151:949–955PubMedCrossRef

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559PubMedCrossRef

Clever YP, Rosenkranz S, Böhm M, Scheller B (2008) Hotline update of clinical trials and registries presented at the ACC and SCAI-ACCi2 meeting 2008 in Chicago. Clin Res Cardiol 97:409–417PubMedCrossRef

10.

The TRANSCEND Investigators (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. doi:10.1016/SO140-6736(08)61242-8

11.

Ripley TR, Harrison D (2008) The power to TRANSCEND. Lancet. doi:10.1016/SO140-6736(08)61243-X

12.

Yusuf S, Diener HC, Sacco RL et al. for the PRoFESS Study Group (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359. doi:10.1056/NEJMoa0804593

13.

GISSI-HF Investigators (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. doi:10.1016/S0140-6736(08)61241-6.

14.

GISSI-Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 354:447–455CrossRef

15.

Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 105:1897–1903PubMedCrossRef

16.

Fonarow GC (2008) Statins and n-3 fatty acid supplementation in heart failure. Lancet. doi:10.1016/S0140-6736(08)61239-8.

17.

van der Harst P, Böhm M, van Gilst WH, van Veldhuisen DJ (2008) The case for statin therapy in chronic heart failure. Clin Res Cardiol 97:139–146PubMedCrossRef

18.

Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248–2261PubMedCrossRef

19.

GISSI-HF investigators (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. doi:10.1016/S0140-6736(08)61241-6.

20.

Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med [Epub ahead of print 2 Sep]

21.

Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R (2008) Analyses of cancer data from three ezetimibe trials. N Engl J Med [Epub ahead of print 2 Sep]

22.

Drazen JM, D’Agostino RB, Ware JH, Morrissey S, Curfman GD (2008) Ezetimibe and cancer—an uncertain association. N Engl J Med [Epub ahead of print 2 Sep]

Title: Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008
Authors: Dr. med. Patrick Müller, MD
Stephan Rosenkranz
Oliver Adam
Florian Custodis
Michael Böhm
Publication date: 01-12-2008
Publisher: D. Steinkopff-Verlag
Published in: Clinical Research in Cardiology / Issue 12/2008
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-008-0729-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2008

Adenosine stress cardiac magnetic resonance imaging for the assessment of ischemic heart disease

Percutaneous septal ablation after unsuccessful surgical myectomy for patients with hypertrophic obstructive cardiomyopathy

ECMO for cardiac rescue in a neonate with accidental amiodarone overdose

Diagnostische Herzkatheteruntersuchung

Contrast-enhanced magnetic resonance imaging reveals early decrease of transmural extent of reperfused acute myocardial infarction

Reverse remodelling through exercise training is more pronounced in non-ischemic heart failure